▶주메뉴 바로가기
▶본문 바로가기
Korea’s leading biopharmaceutical firms — Samsung Biologics and Celltrion — have found themselves in unfamiliar territory, facing disputes with their labor unions amid upbeat earnings. The standoff between Samsung Biologics and its labor union, which began in April, appears likely to continue for some time, as the two sides struggle to find common ground. Samsung Biologics' labor union is weighing whether it should withdraw itself from Samsung Group’s conglomeratewide labor union after a Samsung
Kolon Life Science said Wednesday that it has received a notice of allowance in Canada for a patent covering the manufacturing process of KLS-3021, its oncolytic virus candidate for solid tumors, strengthening the company's intellectual property portfolio and commercialization prospects in North America. The patent covers a large-scale production method for vaccinia-virus-based therapies using suspension-cultured HeLa S3 cells. The technology is designed to improve manufacturing efficiency and s
SK Bioscience said Tuesday it has signed a licensing agreement with the US Centers for Disease Control and Prevention to develop an injectable rotavirus vaccine, expanding its pipeline of vaccines aimed at children in low- and middle-income countries. Under the agreement, SK Bioscience will acquire rights to the CDC's injectable inactivated rotavirus vaccine technology and localize the platform while establishing a manufacturing process designed to improve efficacy and lower production costs. Th
SK Biopharmaceuticals has launched an innovation space to support promising Korean biotech and pharmaceutical companies as they expand into the United States and across the globe. SK Biopharmaceuticals held the official opening ceremony of SK Life Science LinX at its New Jersey-based subsidiary, SK Life Science, last week, the company announced Monday. SK Life Science LinX features a floor space of about 530 square meters with individual rooms, which SK Biopharmaceuticals said will serve as a br
Lotte Biologics will use this year's BIO International Convention to showcase its near-complete Songdo production facility and advanced manufacturing capabilities as it seeks to attract global biopharmaceutical clients. The company said Thursday it will participate in BIO International Convention 2026 in San Diego later this month, marking its fifth consecutive appearance at one of the world's largest biotechnology industry events. A highlight will be the first public showcase of Plant 1 at the
SK Bioscience said Tuesday it had been selected as a supplier of influenza vaccines to UNICEF, securing its first procurement contract with the United Nations agency and expanding its presence in the global public vaccine market. The agreement covers vaccine supplies for both the Southern and Northern Hemispheres. The company has already begun shipments to Southern Hemisphere countries and plans to start deliveries for Northern Hemisphere vaccination programs in September. SK Bioscience expects
Hanmi Pharmaceutical said Monday it has clinched an outlicensing contract with Eli Lilly for sonefpeglutide, its long-acting glucagon-like peptide 2, or GLP-2, drug candidate, in a deal potentially worth up to $1.26 billion. According to the Korean drugmaker, it will receive an upfront payment of $75 million and could earn up to $1.19 billion in additional milestone payments depending on clinical development, regulatory approvals and commercialization. Hanmi Pharmaceutical will also be eligible
Samsung Epis Holdings, the holding company of biosimilar drug developer Samsung Bioepis, said Friday it has established a research and development center in China as part of efforts to strengthen its new drug development capabilities. According to the biotech company, it recently set up a wholly owned subsidiary, Samsung Bioepis China, in Beijing’s Changping district as its first overseas R&D foothold. Samsung Epis Holdings, which was launched in November, noted that the establishment of the new
Celltrion said Friday it has begun primate toxicology studies for its next-generation obesity drug candidate CT-G32, accelerating its development of a first-in-class therapy with advanced effects. According to Celltrion, the toxicology studies, which will evaluate the safety and toxicity profile of CT-G32 in 252 rats and 48 monkeys, are expected to provide critical data to support dose selection and safety evaluation for future clinical trials. The Korean biopharmaceutical firm plans to submit a
GC Biopharma said Wednesday that it would transfer its US affiliate Curevo Vaccine to Eli Lilly and Company in a deal worth up to $1.5 billion. Under the agreement, Lilly will acquire all shares of Curevo and secure rights to amezosvatein, the affiliate’s herpes zoster vaccine candidate currently under development. The deal includes an upfront payment upon closing as well as milestone payments tied to future development and commercialization achievements, GC Biopharma said. The company said the
Chipotle bets on Korea for first bite of Asia
Samsung vs. LG battle for AI cooling heats up
Musinsa posts record earnings on offline, global expansion
One purchase every 0.9 second: Olive Young foreign sales top W1tr
Samsung, SK hynix tax payments surge 167% on chip boom
SK Chemicals eyes European can-coating market
Sept. 2, 2026
June 11, 2026
June 10, 2026
June 9, 2026
June 8, 2026
June 4, 2026
June 2, 2026
June 1, 2026
May 29, 2026
May 29, 2026
May 27, 2026
